CytoSorbents Corporation Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Monmouth Junction, NJ USA
Total Funding:$11.8M
Industry:Medical Equip
Founded:N/A
Lead Investor(s):Bridge Bank

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • CytoSorbents Corporation's estimated annual revenue is currently $32.1M per year.
  • CytoSorbents Corporation received $15.0M in venture funding in April 2018.
  • CytoSorbents Corporation's estimated revenue per employee is $251,000
  • CytoSorbents Corporation's total funding is $11.8M.

Employee Data

  • CytoSorbents Corporation has 128 Employees.
  • CytoSorbents Corporation grew their employee count by 11% last year.
  • CytoSorbents Corporation currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Capintec
$13.3M53N/AN/AN/A
Medlink Imaging
$9.5M38N/AN/AN/A
DRG Internation...
$8.3M33N/AN/AN/A
ACTEON North Am...
$28.9M1157%N/AN/A
ConvaTec
$1185.7M4724N/AN/AN/A
Derma Sciences
N/A126N/AN/AN/A
Topcon Medical ...
$81.1M3235%N/AN/A
Hausmann Indust...
$11.5M46-10%N/AN/A
Oticon USA
$91.9M3667%N/AN/A
HIOSSEN
$86.1M343N/AN/AN/A
Missing a competitor? Contribute!?
Submit

CytoSorbents (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend, ContrastSorb, DrugSorb and others. For more information, please visit the Company's websites: http://www.cytosorbents.com and http://www.cytosorb.com

keywords:Fitness and Wellness,Healthcare,Pharmaceuticals,Physical Security,Security

128

Number of Employees

$32.1M

Revenue (est)

1

Current Jobs

11%

Employee Growth %

$11.8M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Christopher CramerVice President, Business DevelopmentEmail Available
Phillip ChanCEO and PresidentEmail Available
Kathleen BlochChief Financial OfficerEmail Available
Eric MortensenChief Medical OfficerEmail Available
Christian SteinerVP Sales/MarketingEmail Available
Matthew SheahanDirector of OperationsEmail Available
Maryann GrudaDirector BiologyEmail Available
Vincent CapponiCOOEmail Available
Chris CramerVice President, Business DevelopmentEmail Available
Thomas GolobishDirector Of Polymer DevelopmentEmail Available

CytoSorbents Corporation News

09/03/2019 - CytoSorbents to Present at the HC Wainwright 21st Annual ...

MONMOUTH JUNCTION, N.J., Sept. 9, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy ...

09/08/2019 - CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022

MONMOUTH JUNCTION, N.J., Aug. 15, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using ...

09/03/2019 - CytoSorbents Expands CytoSorb Distribution in Latin America ...

MONMOUTH JUNCTION, N.J., Aug. 13, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy ...

CytoSorbents Corporation Funding

DateAmountRoundLead InvestorsReference
2013-10-21$0.7MUndisclosedArticle
2014-03-10$10.2MUndiclosedBrean Capital LLCArticle
2015-01-15$9.5MUndisclosedBrean Capital, LLCArticle
2015-01-26$0.4MUndisclosedTechnology Business Tax Certificate Transfer ProgramArticle
2016-02-02$325.0MUndisclosedNJEDAArticle
2016-07-05$10.0MUndisclosedBridge BankArticle
2016-12-13$0.3MUndisclosedArticle
2017-04-03$11.5MUndisclosedCowen and CompanyArticle
2017-07-06$5.0MUndisclosedLife Sciences Group of Bridge BankArticle
2018-04-05$15.0MUndisclosedBridge BankArticle

CytoSorbents Corporation Executive Hires

DateNameTitleReference
2012-06-21Christian SteinerVP Sales/MarketingArticle
2012-12-03Thomas BocchinoCFOArticle
2013-02-11Ronald BergerInterim CFOArticle
2013-04-16Christopher CramerVP Business DevelopmentArticle
2013-05-14Kathleen P. BlochCFOArticle
2013-07-09Rainer KosankeEuropean Dir Scientific AffairsArticle
2014-12-23Gregory B. Di RussoSVP Clinical DevelopmentArticle
2015-04-28Joerg ScheierEuropean Medical DirectorArticle
2016-01-22Volker HumbertSr Manager Clinical AffairsArticle
2016-11-16Adrian ThomasRegional Sales Dir Western EuropeArticle
2017-05-31Eric MortensenChief Medical OfficerArticle